Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATACAND vs EDARBI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Treatment of hypertension,Treatment of heart failure (NYHA class II-IV and left ventricular systolic dysfunction) to reduce cardiovascular death and hospitalization for heart failure
Treatment of hypertension,Off-label: Diabetic nephropathy, heart failure
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route).
Primarily metabolized by CYP2C9 and CYP3A4; undergoes dehydrogenation and decarboxylation.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
High protein binding: >99%, primarily to serum albumin.
High (>99% bound to serum proteins, mainly albumin).
Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding.
Approximately 0.9 L/kg (total Vdss of about 86 L), indicating extensive distribution into tissues.
Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability.
Absolute bioavailability is about 15% due to extensive first-pass metabolism (CYP2C9, UGT1A3).
No initial dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring.
No dose adjustment is required for patients with mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease (ESRD), caution is advised; no specific dosing recommendations are available due to limited data. Avoid use in patients undergoing dialysis.
For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data).
No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A). For moderate hepatic impairment (Child-Pugh class B), the recommended starting dose is 40 mg once daily; maximum dose is 40 mg once daily. EDARBI should not be used in patients with severe hepatic impairment (Child-Pugh class C).
For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children).
Safety and efficacy in pediatric patients (<18 years) have not been established. Therefore, no dosing recommendation is provided.
Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 m L/min).
No dose adjustment is required for elderly patients (≥65 years). However, as with all patients, initiate at 40 mg once daily; consider cautious titration due to potential greater sensitivity and increased risk of hypotension.
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
No FDA boxed warnings.
Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure.,Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics.,Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function.,Fetal/neonatal morbidity and mortality: As noted in black box warning.,Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney.
Fetal toxicity: Avoid in pregnancy; discontinue if pregnancy occurs,Hypotension in volume-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk in patients with renal impairment or on potassium-sparing diuretics,Avoid use in patients with bilateral renal artery stenosis
Hypersensitivity to candesartan or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
Concomitant use with aliskiren in patients with diabetes,Hypersensitivity to edarbi or any component,Pregnancy
No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously.
No significant food interactions. May be taken with or without food. Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes) and salt substitutes containing potassium, especially in patients with renal impairment or those on concomitant RAAS inhibitors or potassium-sparing diuretics.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal renal damage, oligohydramnios, and skull ossification defects. Second and third trimester exposure: Increased risk for oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and anuria. Use is contraindicated in pregnancy, especially in second and third trimesters.
No data on candesartan in human milk; animal studies detect drug in milk. M/P ratio unknown. Avoid breastfeeding due to potential risk of neonatal hypotension and renal impairment.
No data on azilsartan medoxomil (EDARBI) excretion in human milk; effects on the breastfed infant and milk production are unknown. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio unknown.
Avoid use in second and third trimesters due to fetotoxicity. If inadvertent exposure occurs, discontinue drug immediately. No dose adjustment recommended for first trimester use, but consider alternative antihypertensive agent throughout pregnancy.
EDARBI is not recommended during pregnancy; if pregnancy is detected, discontinue as soon as possible. No specific dose adjustments have been established for use in pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure, but no data are available to guide dosing.
ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment.
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) with high receptor affinity and a long half-life (~11 hours), allowing once-daily dosing. It is a prodrug that is rapidly hydrolyzed to the active moiety azilsartan. Onset of action within 2 weeks; maximum effect may take 4-6 weeks. Monitor renal function and serum potassium, especially in patients with renal impairment, diabetes, or those taking NSAIDs or potassium-sparing diuretics. Avoid use in pregnancy (category D). Dose adjustment recommended for patients with hepatic impairment (Child-Pugh class B).
Take ATACAND exactly as prescribed, typically once daily with or without food.,Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs.,May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known.,Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider.,Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately.,Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea).
Take exactly as prescribed, usually once daily, with or without food.,Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms such as dizziness, fainting, rapid heartbeat, or signs of kidney problems (e.g., swelling, decreased urination).,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose. Do not double the dose.,Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATACAND vs EDARBI, answered by our medical review team.
ATACAND is a Angiotensin II Receptor Blocker that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. EDARBI is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATACAND and EDARBI depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATACAND is: Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.. The standard adult dose of EDARBI is: EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATACAND and EDARBI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATACAND is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, sk. EDARBI is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.